Anne Madroszyk

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel et al. · The Lancet Oncology · 2011 · 265 citations

Medicine, Immunology, Oncology +15

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Élisabeth Quoix, H. Léna, György Losonczy et al. · The Lancet Oncology · 2015 · 207 citations

Medicine, Immunology, Oncology +13

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

C. Chouaïd, C. Dujon, Pascal Dô et al. · Lung Cancer · 2014 · 187 citations

Medicine, Oncology, Surgery +8

Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

M. Duruisseaux, Benjamin Besse, J. Cadranel et al. · Oncotarget · 2017 · 162 citations · Full text

Medicine, Oncology, Pharmacology +14

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Nathalie Baize, I. Monnet, Laurent Greillier et al. · The Lancet Oncology · 2020 · 153 citations

Medicine, Oncology, Pharmacology +13